Here is the design of a clinical trial:

Official Title: The Comparative Analysis of the Effects on Plaque Volume and Tissue Characteristics Between Combined Therapy With STAatin Plus FENOfibrate and Statin Alone in Mild to Moderate, Non- Intervened Coronary Artery Stenosis (STAFENO Trial)

Included conditions:
- Coronary Artery Disease

Study Armgroups:
- {'label': 'Rosuvastatin and fenofibrate', 'type': 'EXPERIMENTAL', 'description': 'Combination therapy: rosuvastatin 10 mg and fenofibrate 160 mg per day', 'interventionNames': ['Drug: Rosuvastatin and fenofibrate']}
- {'label': 'Rosuvastatin alone', 'type': 'ACTIVE_COMPARATOR', 'description': 'Rosuvastatin 10 mg per day', 'interventionNames': ['Drug: Rosuvastatin alone']}

Interventions:
- {'type': 'DRUG', 'name': 'Rosuvastatin and fenofibrate', 'description': 'Combination therapy: rosuvastatin 10 mg and fenofibrate 160 mg per day', 'armGroupLabels': ['Rosuvastatin and fenofibrate'], 'otherNames': ['Combination therapy with rosuvastatin and fenofibrate']}
- {'type': 'DRUG', 'name': 'Rosuvastatin alone', 'description': 'Rosuvastatin 10mg per day', 'armGroupLabels': ['Rosuvastatin alone'], 'otherNames': ['Rosuvastatin alone therapy']}

Primary Outcomes:
- {'measure': 'Percent and Absolute changes of Necrotic Core volume in non-culprit intermediate lesions', 'description': 'Percent and Absolute changes of Necrotic Core volume in non-culprit intermediate lesions by VH-IVUS', 'timeFrame': 'After 12±2 months treatment'}

Please estimate the sample size based on the assumption: 
80% power, standard deviation of 7.82, two-sided alpha level of 0.05, dropout rate of 20%.
Sample size calculations
        Based on a previous study [15], a sample size of approximately 42 patients per treatment group was calculated to provide 80% power (assuming a standard deviation of 7.82) to detect a difference of 4.78 in percentage NCV and to detect the superiority of statin plus fenofibrate compared to statin alone with a two-sided alpha level of 0.05. With a statin plus fenofibrate:satin alone sampling ratio of 1:1 and a dropout rate of 20%, a final sample size of 53 patients per treatment group (total 106 patients) was specified in order to provide an adequate number of evaluable patients. To the best of the researchersâ knowledge, no study has been conducted on the change of tissue characteristics after fenofibrate treatment. We hypothesized that fenofibrate has an effect on percentage NCV as much as that of 10âmg atorvastatin [15]. In addition, a previous study [16] consisting of 100 patients with non-significant lesions demonstrated a significant decrease in NCV in the rosuvastatin (10âmg/day) treated group but not in the simvastatin treated group (20âmg/day).